 Suramin
"Suramin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
| Descriptor ID |
D013498
|
| MeSH Number(s) |
D02.455.426.559.847.638.555.750 D02.886.645.600.080.050.650.750 D04.615.638.555.750
|
| Concept/Terms |
Suramin Sodium- Suramin Sodium
- Sodium, Suramin
- Suramin, Hexasodium Salt
- Hexasodium Salt Suramin
- Salt Suramin, Hexasodium
|
Below are MeSH descriptors whose meaning is more general than "Suramin".
Below are MeSH descriptors whose meaning is more specific than "Suramin".
This graph shows the total number of publications written about "Suramin" by people in this website by year, and whether "Suramin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Suramin" by people in Profiles.
-
Rahman MM, Watton PN, Neu CP, Pierce DM. A chemo-mechano-biological modeling framework for cartilage evolving in health, disease, injury, and treatment. Comput Methods Programs Biomed. 2023 Apr; 231:107419.
-
Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012 Jul; 70(1):49-56.
-
Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1019-29.
-
Fedorov YV, Rosenthal RS, Olwin BB. Oncogenic Ras-induced proliferation requires autocrine fibroblast growth factor 2 signaling in skeletal muscle cells. J Cell Biol. 2001 Mar 19; 152(6):1301-5.
-
I?iguez C, Larrod? P, Mayordomo JI, Mauri JA, Tr?s A, Morales F. [Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] . Neurologia. 2000 Oct; 15(8):343-51.
-
Voelkel NF, Hoeper M, Maloney J, Tuder RM. Vascular endothelial growth factor in pulmonary hypertension. Ann N Y Acad Sci. 1996 Oct 31; 796:186-93.
-
DeAntoni E, Crawford ED. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. Urologe A. 1995 Sep; 34(5):382-8.
-
Holland EJ, Stein CA, Palestine AG, LaRocca R, Chan CC, Kuwabara T, Myers CE, Thomas R, McAtee N, Nussenblatt RN. Suramin keratopathy. Am J Ophthalmol. 1988 Aug 15; 106(2):216-20.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|